ML Bio Solutions, Inc.
🇺🇸United States
Clinical Trials
3
Active:2
Completed:1
Trial Phases
2 Phases
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 3
1 (50.0%)Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
Phase 3
Active, not recruiting
- Conditions
- Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
- Interventions
- Drug: BBP-418 (ribitol)Other: Placebo
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ML Bio Solutions, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT05775848
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸University of California Irvine, Irvine, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Study of BBP-418 in Patients With LGMD2I
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- ML Bio Solutions, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04800874
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Biomarker Development in LGMD2i
Completed
- Conditions
- Limb Girdle Muscular DystrophyMuscular Dystrophies
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- ML Bio Solutions, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04202627
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸University of Florida, Gainesville, Florida, United States
News
No news found